Furthermore, EGFR mutations in PSCCE are rare but do exist, especially gefitinib associated mutations such as L858R, therefore gefitinib-based gene targeted therapy at EGFR but not KRAS and PIK3CA genes, probably should be included in this carcinoma treatment regimens for patients harboring L858R mutation. This evidence concerns the gene EGFR and carcinoma.